{ "as_of": "2026-11-06", "cmr": "ca-cm-kg/CSE/MDMA", "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.", "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Pharmala Biotech Holdings Inc. (CSE: MDMA) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Pharmala Biotech Holdings Inc., listed on the CSE under ticker MDMA, with ISIN CA71719L1067 and LEI 25490067ZSSSB85I9Y16. Its security type is Corporate, its segment is not on the record, its sector is Life Sciences, and its jurisdiction is Ontario (CA-ON). The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 7 filings in the twelve months to 2026-11-06, on 6 filing days, all of them newswire releases. The median gap between filing days is 28 days. The latest filing is dated 2026-11-05, 1 day before the record date, and is a newswire release. The CSE median gap is 19.5 days across 724 issuers, with a median of 6.0 filings and a median latency of 17.0 days. The Life Sciences sector median gap is 17.5 days across 200 issuers, with a median of 7.0 filings and a median latency of 14 days.\n\n## Auditor\n\nThe auditor of record is Clearhouse LLP, and its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move lines. The halt flag is listed, not halted.\n\n## Orderability\n\nUnder the rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, the outcome for the client category Paragraph (o) of the definition is signal ACM-200, determinable. The outcome for the client category Paragraph (q) of the definition is signal ACM-200, determinable. The chapter is as of 2026-11-04.\n\n## Coverage\n\nThe field has not been read. The number of research houses named on the issuer's investor-relations page is not on the record.\n\n## Open research\n\nThe field has not been read. The number of openly published research notes is not on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. The issuer has no sealed years on the record. The live record began on 2026-09-10. Years 2021, 2022, 2023, 2024, 2025 and 2026 are sealed in the store but not served as of a date, and the as-of answer is not_sealed.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://thecse.com/api/webapi/listed-companies/ (identity.exchange)\n- https://www.marketscreener.com/quote/stock/PHARMALA-BIOTECH-HOLDINGS-131624716/company (identity.isin)\n- https://api.gleif.org/api/v1/lei-records/25490067ZSSSB85I9Y16 (identity.jurisdiction)\n- https://mcp.ca-cm-kg.ai/events/CSE/MDMA (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://thecse.com/listings/pharmala-biotech-holdings-inc/ (the auditor)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.ca-cm-kg.ai/record/CSE/MDMA (the record)\n", "market": "CA", "node": "ca-cm-kg", "numbers": { "as_of_depth": { "issuer_years_sealed": [], "live_record_began": "2026-09-10", "node_history_from": null, "node_years_sealed": [], "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06", "record_version": 1, "sealed": false, "store_years_sealed_not_served": [ "2021", "2022", "2023", "2024", "2025", "2026" ] }, "auditor": { "auditor": { "read_by": "CSE", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/listings/pharmala-biotech-holdings-inc/", "state": "sourced", "value": "Clearhouse LLP" }, "auditor_firm_id": { "market": "CA", "state": "not_on_record" }, "auditor_location": { "market": "CA", "state": "not_on_record" }, "changes": [] }, "cmr": "ca-cm-kg/CSE/MDMA", "coverage": { "note": "the coverage field has not been read for this issuer", "state": "not_read" }, "disclosure": { "against": { "exchange": { "issuers": 724, "median_cadence_gap_days": 19.5, "median_filings": 6, "median_latency_days": 17, "name": "CSE" }, "sector": { "issuers": 200, "median_cadence_gap_days": 17.5, "median_filings": 7, "median_latency_days": 14, "name": "Life Sciences" } }, "by_type": { "newswire_release": 7 }, "cadence_median_gap_days": 28, "filing_days": 6, "filings": 7, "latency_days": 1, "latest": [ { "category": null, "date": "2026-11-05", "source": "https://www.globenewswire.com/news-release/2026/11/05/3396385/0/en/pharmala-signs-agreement-and-initiates-r-d-with-corealis-pharma-for-gmp-manufacturing-of-its-patented-ala-002-drug-product.html", "title": "PharmAla Signs Agreement and Initiates R&D with Corealis", "type": "newswire_release" }, { "category": null, "date": "2026-10-08", "source": "https://www.globenewswire.com/news-release/2026/10/08/3377694/0/en/rua-bioscience-and-pharmala-biotech-partner-to-supply-medicinal-mdma-in-new-zealand.html", "title": "Rua Bioscience and PharmAla Biotech partner to supply", "type": "newswire_release" }, { "category": null, "date": "2026-09-17", "source": "https://www.globenewswire.com/news-release/2026/09/17/3363984/0/en/pharmala-biotech-provides-corporate-update-change-of-auditor-retention-of-watertower-research-and-oak-hill.html", "title": "PharmAla Biotech Provides Corporate Update: Change of", "type": "newswire_release" }, { "category": null, "date": "2026-04-20", "source": "https://www.globenewswire.com/news-release/2026/04/20/3276976/0/en/PharmAla-Biotech-Positioned-to-Supply-U-S-Expanded-Access-Pathway-for-MDMA-Established-by-Presidential-Executive-Order.html", "title": "PharmAla Biotech Positioned to Supply U.S. Expanded Access", "type": "newswire_release" }, { "category": null, "date": "2026-04-20", "source": "https://www.globenewswire.com/fr/news-release/2026/04/20/3276976/0/en/pharmala-biotech-positioned-to-supply-u-s-expanded-access-pathway-for-mdma-established-by-presidential-executive-order.html", "title": "PharmAla Biotech Positioned to Supply U.S. Expanded Access", "type": "newswire_release" } ], "latest_filing_date": "2026-11-05", "read": "the node's event lines (list_events_since), as get_filings serves them", "source": "https://mcp.ca-cm-kg.ai/events/CSE/MDMA", "window": { "from": "2025-11-06", "to": "2026-11-06" } }, "identity": { "exchange": { "read_by": "thecse.com listed-companies API (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/api/webapi/listed-companies/", "state": "sourced", "value": "CSE" }, "isin": { "read_by": "Tavily search + regex extraction from page text", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.marketscreener.com/quote/stock/PHARMALA-BIOTECH-HOLDINGS-131624716/company", "state": "sourced", "value": "CA71719L1067" }, "jurisdiction": { "read_by": "GLEIF LEI record (LEI per the LEI column)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://api.gleif.org/api/v1/lei-records/25490067ZSSSB85I9Y16", "state": "sourced", "value": "Ontario (CA-ON)" }, "lei": { "read_by": "GLEIF name-exact", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://api.gleif.org/api/v1/lei-records/25490067ZSSSB85I9Y16", "state": "filled", "value": "25490067ZSSSB85I9Y16" }, "name": { "read_by": "thecse.com listed-companies API (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/api/webapi/listed-companies/", "state": "sourced", "value": "Pharmala Biotech Holdings Inc." }, "sector": { "read_by": "thecse.com listed-companies API (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/api/webapi/listed-companies/", "state": "sourced", "value": "Life Sciences" }, "security_type": { "read_by": "thecse.com listed-companies API (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/api/webapi/listed-companies/", "state": "sourced", "value": "Corporate" }, "segment": { "market": "CA", "state": "not_on_record" }, "ticker": { "read_by": "thecse.com listed-companies API (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://thecse.com/api/webapi/listed-companies/", "state": "sourced", "value": "MDMA" }, "website": { "market": "CA", "state": "not_on_record" } }, "licensed": { "columns": [ "licensor", "entitlement", "title", "date", "source" ], "rows": [], "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded." }, "lifecycle": { "delisting": [], "domicile_change": [], "listing": [], "name_change": [], "segment_move": [] }, "market": "CA", "node": "ca-cm-kg", "numbers_hash": "sha256:e7bccb59573126e13886079fb736fc088d7c39a2516c9f004bc627e3b5468037", "open_research": { "rows": [], "state": "not_read" }, "orderability": { "chapter_as_of": "2026-11-04", "client_categories": [ "Paragraph (o) of the definition", "Paragraph (q) of the definition" ], "outcomes": { "Paragraph (o) of the definition": { "determinable": true, "signal": "ACM-200" }, "Paragraph (q) of the definition": { "determinable": true, "signal": "ACM-200" } }, "read": { "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group", "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json", "door": "https://mcp.ca-cm-kg.ai/mcp", "tool": "get_orderability" }, "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1", "section": "ca.aio.v11" }, "record": { "as_of": "2026-11-06", "url": "https://mcp.ca-cm-kg.ai/record/CSE/MDMA", "version": 1 }, "schema": "research-numbers v0.1 (USR-01, 2026-11-11)", "status": { "read_date": "2026-11-08", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100", "value": "listed, not halted" } }, "numbers_hash": "sha256:e7bccb59573126e13886079fb736fc088d7c39a2516c9f004bc627e3b5468037", "path": "/ca/CSE/MDMA", "schema": "research-page v0.1 (USR-02, 2026-11-11)", "sections": [ { "id": "identity", "text": "The issuer is Pharmala Biotech Holdings Inc., listed on the CSE under ticker MDMA, with ISIN CA71719L1067 and LEI 25490067ZSSSB85I9Y16. Its security type is Corporate, its segment is not on the record, its sector is Life Sciences, and its jurisdiction is Ontario (CA-ON). The listing status is listed, not halted.", "title": "Identity and listing" }, { "id": "disclosure", "text": "The record holds 7 filings in the twelve months to 2026-11-06, on 6 filing days, all of them newswire releases. The median gap between filing days is 28 days. The latest filing is dated 2026-11-05, 1 day before the record date, and is a newswire release. The CSE median gap is 19.5 days across 724 issuers, with a median of 6.0 filings and a median latency of 17.0 days. The Life Sciences sector median gap is 17.5 days across 200 issuers, with a median of 7.0 filings and a median latency of 14 days.", "title": "The disclosure read" }, { "id": "auditor", "text": "The auditor of record is Clearhouse LLP, and its location is not on the record. The record holds no auditor changes.", "title": "Auditor" }, { "id": "events", "text": "The record holds no listing, delisting, name change, domicile change or segment move lines. The halt flag is listed, not halted.", "title": "Events and halts" }, { "id": "orderability", "text": "Under the rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, the outcome for the client category Paragraph (o) of the definition is signal ACM-200, determinable. The outcome for the client category Paragraph (q) of the definition is signal ACM-200, determinable. The chapter is as of 2026-11-04.", "title": "Orderability" }, { "id": "coverage", "text": "The field has not been read. The number of research houses named on the issuer's investor-relations page is not on the record.", "title": "Coverage" }, { "id": "open_research", "text": "The field has not been read. The number of openly published research notes is not on the record.", "title": "Open research" }, { "id": "licensed", "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.", "title": "Licensed" }, { "id": "depth", "text": "The market's vintage is not sealed. The issuer has no sealed years on the record. The live record began on 2026-09-10. Years 2021, 2022, 2023, 2024, 2025 and 2026 are sealed in the store but not served as of a date, and the as-of answer is not_sealed.", "title": "As-of depth" }, { "id": "sources", "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.", "title": "Sources" } ], "sources": [ { "for": "identity.exchange", "source": "https://thecse.com/api/webapi/listed-companies/" }, { "for": "identity.isin", "source": "https://www.marketscreener.com/quote/stock/PHARMALA-BIOTECH-HOLDINGS-131624716/company" }, { "for": "identity.jurisdiction", "source": "https://api.gleif.org/api/v1/lei-records/25490067ZSSSB85I9Y16" }, { "for": "the disclosure lines", "source": "https://mcp.ca-cm-kg.ai/events/CSE/MDMA" }, { "for": "the halt flag", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100" }, { "for": "the auditor", "source": "https://thecse.com/listings/pharmala-biotech-holdings-inc/" }, { "for": "the orderability chapter", "source": "https://mcp.ca-cm-kg.ai/book/aio.json" }, { "for": "the record", "source": "https://mcp.ca-cm-kg.ai/record/CSE/MDMA" } ], "title": "Pharmala Biotech Holdings Inc. (MDMA) — research page", "writer": { "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers", "engine": "claude-haiku-5-5" } }